 ATLANTA, GA, March 30, 2020 GLOBE NEWSWIRE -- via NEWMEDIAWIRE --GeoVax Labs, Inc. GOVX, a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today commented on the passage of the Coronavirus Aid, Relief, and Economic Security Act CARES ACT, which was signed into law by President Trump on March 27, 2020. Among the many provisions of this unprecedented 2 trillion economic stimulus bill, 27 billion of emergency funding is appropriated for the Public Health and Social Services Emergency Fund to prevent, prepare for, and respond to the current coronavirus pandemic, including the development of countermeasures and vaccines. GeoVax is using itsGV-MVA-VLPTM vaccine platform and expertise to develop vaccine candidates using genetic sequences from SARS-CoV-2, the virus responsible for the ongoing COVID-19 outbreak. 